New allergy drug shows promise in early trial

NCT ID NCT03570957

Completed Symptom relief Sponsor: Tanabe Pharma Corporation Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage study tested a single dose of the investigational drug MT-2990 in 75 adults with seasonal allergic rhinitis triggered by Japanese cedar pollen. The main goals were to check the drug's safety, how the body processes it, and whether it can reduce allergy symptoms when patients are exposed to pollen in a controlled chamber. Results will help decide if larger studies are warranted.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: MT-2990
What this could lead to: If successful, this could lead to a new treatment option for seasonal allergic rhinitis caused by Japanese cedar pollen.
What could go wrong: This is an early Phase 1 study with only 75 participants, so results may not confirm effectiveness or safety in larger populations. The drug may cause side effects or fail to provide meaningful symptom relief.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SEASONAL ALLERGIC RHINITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

seasonal allergic rhinitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SEASONAL ALLERGIC RHINITIS

Contacts and locations

Locations

Investigational Site

Tokyo, Japan

More trials for these conditions

Other studies related to the condition(s) this trial covers.